Schonfeld Strategic Advisors’s CytomX Therapeutics CTMX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$318K	Buy	+67,732	New	+$344K	﹤0.01%	1555
2025 Q2	–	Sell	-589,332	Closed	-$375K	–	2121
2025 Q1	$375K	Sell	589,332 -791,468	-57%	-$614K	﹤0.01%	1705
2024 Q4	$1.42M	Buy	1,380,800 +169,000	+14%	+$182K	0.01%	978
2024 Q3	$1.43M	Sell	1,211,800 -163,490	-12%	-$208K	0.01%	1032
2024 Q2	$1.68M	Buy	1,375,290 +100,783	+8%	+$201K	0.01%	982
2024 Q1	$2.78M	Buy	+1,274,507	New	+$2.35M	0.02%	874
2022 Q1	–	Sell	-19,800	Closed	-$85K	–	2646
2021 Q4	$85K	Buy	+19,800	New	+$116K	﹤0.01%	1905

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Schonfeld Strategic Advisors's CTMX Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in CytomX Therapeutics (CTMX) in Q1 2026: 67,732 shares worth $318K. The stake represents ﹤0.01% of the portfolio and ranks #1555 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in CTMX as recently as Q1 2025.

Schonfeld Strategic Advisors first reported a position in CTMX in Q4 2021 and has held it in 7 quarters since. The position peaked at $2.78M in Q1 2024. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

Schonfeld Strategic Advisors held 67,732 shares of CytomX Therapeutics worth $318K as of Q1 2026.
CytomX Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
CytomX Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1555 holding.
Schonfeld Strategic Advisors first reported a position in CytomX Therapeutics in Q4 2021 and has held it in 7 quarters since.
Schonfeld Strategic Advisors's CytomX Therapeutics position peaked at $2.78M in Q1 2024.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.